Copiktra

Digital Pharmacist

The RxWiki Digital Pharmacist stamp of approval lets you know that this content has been created and reviewed by a licensed pharmacist.

Copiktra treats certain types of leukemia and lymphoma, two types of blood cancers. Grapefruit and grapefruit juice may interact with Copiktra.

Copiktra Overview

Reviewed: September 26, 2018
Updated: 

Copiktra is a prescription medication used to treat relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma and relapsed or refractory follicular lymphoma.

Copiktra belongs to a group of drugs called kinase inhibitors. A kinase is an enzyme that promotes cell growth. There are many types of kinases, which control different phases of cell growth. By blocking a particular enzyme from working, this medication can slow the growth of cancer cells.  

This medication comes in capsule form and is taken twice daily, swallowed whole, with or without food.

Common side effects include tiredness, fever, cough, and nausea.

How was your experience with ?

First, a little about yourself

Tell us about yourself in a few words?

What tips would you provide a friend before taking ?

What are you taking for?

Choose one
  • Other

How long have you been taking it?

Choose one
  • Less than a week
  • A couple weeks
  • A month or so
  • A few months
  • A year or so
  • Two years or more

How well did work for you?

Did you experience many side effects while taking this drug?

How likely would you be to recommend to a friend?

Copiktra Drug Class

Back to Top

Copiktra is part of the drug class:

Copiktra FDA Warning

Back to Top

WARNING: FATAL AND SERIOUS TOXICITIES: INFECTIONS, DIARRHEA OR COLITIS, CUTANEOUS REACTIONS, and PNEUMONITIS.

  • Fatal and/or serious infections occurred in 31% of Copiktra-treated patients. Monitor for signs and symptoms of infection. Withhold Copiktra if infection is suspected.

  • Fatal and/or serious diarrhea or colitis occurred in 18% of Copiktra-treated patients. Monitor for the development of severe diarrhea or colitis. Withhold Copiktra.

  • Fatal and/or serious cutaneous reactions occurred in 5% of Copiktra-treated patients. Withhold Copiktra.

  • Fatal and/or serious pneumonitis occurred in 5% of Copiktra-treated patients. Monitor for pulmonary symptoms and interstitial infiltrates. Withhold Copiktra.